Pharma BD Deal Intelligence
Vertex buying Semma Therapeutics for $950 million to develop stem cell-derived insulin-producing islet cell replacement therapies
Vertex announced zimislecel (VX-880) is in the Phase 3 portion of its Phase 1/2/3 study with global regulatory submissions expected in 2026, and that…
Positive zimislecel Phase 1/2 data at ADA 2025: all 12 dosed participants restored endogenous insulin secretion (A1C <7%, time-in-range >70%);…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Vertex Pharmaceuticals acquired Semma Therapeutics for $950 million in cash, gaining stem cell-derived human islet cell therapy technology for type 1 diabetes, including methods for producing functional pancreatic beta cells and a proprietary cell encapsulation device enabling implantation without chronic immunosuppression.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. (this deal) | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
| Vertex Pharmaceuticals Incorporated / ViaCyte Inc. | 2022 | $320M | 60 |
← Browse all deals · How we score deals
More: 2019 deals · Vertex Pharmaceuticals Incorporated deals · Gene Therapy deals